paroxetine has been researched along with Weight Gain in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Acosta, A; Bielinski, SJ; Camilleri, M; Cifuentes, L; Decker, PA; Gonzalez-Izundegui, D; Hurtado, MD; Moyer, AM; Ricardo-Silgado, ML; Singh, S | 1 |
| Blum, WF; Colla, M; Daseking, E; Deuschle, M; Gilles, M; Heuser, I; Kopf, D; Krumm, B; Lederbogen, F; Schilling, C; Weber-Hamann, B; Wudy, SA | 1 |
| Cedro, C; D'Amico, G; D'Arrigo, C; Di Rosa, AE; La Torre, D; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R | 1 |
| Merlob, P; Stahl, B; Sulkes, J | 1 |
| Cohen, A; Dannon, PN; Grunhaus, L; Iancu, I; Kotler, M; Lowengrub, K | 1 |
| Albert, U; Bogetto, F; Maina, G; Salvi, V | 1 |
| Battaglia, G; Carrasco, GA; Chen, Z; Muma, NA; Shankaran, M; Sripathirathan, K; Tetzlaff, J; Van De Kar, LD | 1 |
| Bahk, WM; Chae, JH; Jun, TY; Kim, TS; Pae, CU; Rhee, WI; Yoon, SJ | 1 |
| Colman, SA; Harrison, GA; Hong, JP; Lee, MS; Lee, P; Liu, CY; Raskin, J; Ruschel, S; Shu, L; Wang, CY; Xu, X | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Amsterdam, JD; Garcia-España, F; Goodman, D; Hooper, M; Hornig-Rohan, M | 1 |
| Begley, A; Mazumdar, S; Mulsant, B; Pollock, BG; Stack, J; Weber, E | 1 |
| Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME | 1 |
9 trial(s) available for paroxetine and Weight Gain
| Article | Year |
|---|---|
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarkers; Body Mass Index; Cyclohexanols; Depression; Female; Humans; Leptin; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Time Factors; Treatment Outcome; Up-Regulation; Venlafaxine Hydrochloride; Weight Gain; Young Adult | 2013 |
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Pirenzepine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain | 2003 |
Three year naturalistic outcome study of panic disorder patients treated with paroxetine.
Topics: Adult; Agoraphobia; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Obesity; Panic Disorder; Paroxetine; Prevalence; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Treatment Outcome; Weight Gain | 2004 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obesity; Obsessive-Compulsive Disorder; Paroxetine; Patient Compliance; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2004 |
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Female; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating; Venlafaxine Hydrochloride; Weight Gain | 2006 |
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Brazil; China; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Heart Rate; Humans; Korea; Male; Middle Aged; Pain; Pain Measurement; Paroxetine; Psychiatric Status Rating Scales; Taiwan; Thiophenes; Weight Gain | 2007 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Weight Gain; Weight Loss | 2000 |
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Longitudinal Studies; Male; Middle Aged; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2000 |
4 other study(ies) available for paroxetine and Weight Gain
| Article | Year |
|---|---|
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Topics: Body Weight; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Humans; Paroxetine; Phenotype; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2022 |
Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Breast Feeding; Case-Control Studies; Depressive Disorder; Female; Humans; Infant; Male; Paroxetine; Patient Compliance; Prospective Studies; Weight Gain | 2004 |
Paroxetine is effective in desensitizing 5-HT1A receptor function in adult offspring exposed prenatally to cocaine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenocorticotropic Hormone; Animals; Cocaine; Corticosterone; Female; Fetus; Growth; Oxytocin; Paroxetine; Piperazines; Pregnancy; Prolactin; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Renin; Weight Gain | 2005 |
Breast enlargement during chronic antidepressant therapy.
Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia; Male; Menopause; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Weight Gain | 1997 |